ArticleDiscover oncology2026

AFP confers the resistance of lenvatinib in hepatocellular carcinoma by activating PI3K/AKT/LDHA signaling axis.

Weimei Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.